Vincent Hervé

Mr. Vincent Hervé

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FDFrederik Desmarais
Frederik Desmarais
VHVincent Hervé
Vincent Hervé
KBKarl-Frederik Bergeron
Karl-Frederik Bergeron
GRGaétan Ravaut
Gaétan Ravaut
MPMorgane Perrotte
Morgane Perrotte
Catherine MounierCatherine Mounier
Catherine Mounier
Apolipoprotein D (ApoD) is a secreted lipocalin associated with neuroprotection and lipid metabolism. In rodent, the bulk of its expression occurs in the central nervous system. Despite this, ApoD has profound effects in peripheral tissues, indicating that neural ApoD may reach peripheral organs. We endeavor to determine if cerebral ApoD can reach the circulation and accumulate in peripheral tissues. Three hours was necessary for over 40% of all the radiolabeled human ApoD (hApoD), injected bilaterally, to exit the central nervous system (CNS). Once in circulation, hApoD accumulates mostly in the kidneys/urine, liver, and muscles. Accumulation specificity of hApoD in these tissues was strongly correlated with the expression of lowly glycosylated basigin (BSG, CD147). hApoD was observed to pass through bEnd.3 blood brain barrier endothelial cells monolayers. However, cyclophilin A did not impact hApoD internalization rates in bEnd.3, indicating that ApoD exit from the brain is either independent of BSG or relies on additional cell types. Overall, our data showed that ApoD can quickly and efficiently exit the CNS and reach the liver and kidneys/urine, organs linked to the recycling and excretion of lipids and toxins. This indicated that cerebral overexpression during neurodegenerative episodes may serve to evacuate neurotoxic ApoD ligands from the CNS.

27 September 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VHVincent Hervé
Vincent Hervé
LBLaurie Bonenfant
Laurie Bonenfant
MAMathilde Amyot
Mathilde Amyot
RBRime Balafrej
Rime Balafrej
OAObai Bin Ka’b Ali
Obai Bin Ka’b Ali
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
Summary: In Alzheimer’s disease, there is an imbalance in neurotransmitter release and altered neuronal activation. We present a novel approach to analyze neuronal activity by combining local field potential (LFP) recording with microdialysis within the same animal. This method measures glutamate and GABA levels following chronic hippocampal amyloid-beta oligomer (Aβo) injections in rats. We outline the design of our electrode and canula, the surgical procedure, and the steps for LFP recording, interstitial fluid collection, and Aβo injections simultaneously in living animal. Graphical

23 December 2025 in Alzheimer's & Dementia
Verified
Journal Article
Open access
VHVincent Hervé
Vincent Hervé
OKObai BinB KaAli
Obai BinB KaAli
HBHabib Benali
Habib Benali
JBJonathan Brouillette
Jonathan Brouillette
Background: One of the main neuropathological hallmarks of Alzheimer's disease (AD) is the accumulation of amyloid‐beta oligomers (Aβo), which begins in the brain approximately 15 years prior to the onset of clinical symptoms. Aβo‐induced neuronal hyperactivity has emerged as an early functional characteristic of AD, contributing to synaptic deficits, memory impairment, and neurodegeneration. Several studies suggest that Aβo reduce the inhibitory activity of the GABAergic system, leading to excessive activation of the glutamatergic system. The aim of this study is to investigate the impact of Aβo on neuronal activity and neurotransmitter release within the same animal model. Method: A microdialysis probe is implanted in the right hippocampus of a rat model to deliver Aβ oligomers over five consecutive days and to collect interstitial fluid (ISF) samples before, during, and after the injections. In addition, five electrodes are implanted within the hippocampi and default mode network of the rats to record neuronal activity. Result: Firstly, we demonstrated through immunohistochemistry that our Aβo injections are successfully delivered into the hippocampus. Our initial results demonstrate the ability to record local field potential (LFP) signals in five distinct brain areas and to detect several neurotransmitters (glutamate, GABA, serine, taurine, glutamine, and glycine) in ISF samples. Chronic Aβo injections resulted in a clear time‐dependent increase in delta power and a progressive decrease in higher frequency bands (theta, alpha, beta, gamma) in the injected hippocampus. In the non‐injected (left) hippocampus, stable trends were observed initially, with a late onset increase in delta power and reduction in higher frequency power by day 5 in the Aβo group. Preliminary results on the quantification of neurotransmitters, including glutamate and GABA, are currently being analyzed but have already been detected by mass spectrometry in the ISF fractions. Conclusion: This study will provide novel insights into the relationship between Aβo‐induced changes in neuronal activity and neurotransmitter release, contributing to a better understanding of the neurodegenerative processes involved in early AD.

24 March 2025 in STAR Protocols
Verified
Journal Article
Open access
VHVincent Hervé
Vincent Hervé
LBLaurie Bonenfant
Laurie Bonenfant
MAMathilde Amyot
Mathilde Amyot
RBRime Balafrej
Rime Balafrej
OAObai Bin Ka’b Ali
Obai Bin Ka’b Ali
Jonathan BrouilletteJonathan Brouillette
Jonathan Brouillette
In Alzheimer's disease, there is an imbalance in neurotransmitter release and altered neuronal activation. Here, we present a protocol approach to analyze neuronal activity by combining local field potential (LFP) recording with microdialysis within the same animal. We describe steps for measuring glutamate and GABA levels following hippocampal amyloid-beta oligomer (Aβo) injections in rats. We then detail procedures for assembling the electrode and cannula, surgical implantation and simultaneous in vivo LFP recording, interstitial fluid collection, and Aβo injections.